ArticleInternational journal of nanomedicine2011
Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
Article in International journal of nanomedicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies.Medicina (Kaunas, Lithuania) · 2024Review
- Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cells.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment.JID innovations : skin science from molecules to population health · 2023Review
- Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics.Beilstein journal of nanotechnology · 2023Review
- Folic acid functionalization for targeting self-assembled paclitaxel-based nanoparticles.RSC advances · 2022Article
- Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy.Frontiers in bioengineering and biotechnology · 2022Article
- DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment.Advanced pharmaceutical bulletin · 2021Review
- A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy.Nano-micro letters · 2020Review
- Strategies for Precise Engineering and Conjugation of Antibody Targeted-nanoparticles for Cancer Therapy.Current medical science · 2020Review
- Co-delivery of Dacarbazine and All-Trans Retinoic Acid (ATRA) Using Lipid Nanoformulations for Synergistic Antitumor Efficacy Against Malignant Melanoma.Nanoscale research letters · 2020Article
- Developing TRAIL/TRAIL death receptor-based cancer therapies.Cancer metastasis reviews · 2018Review
- Photodynamic Therapy for Metastatic Melanoma Treatment: A Review.Technology in cancer research & treatment · 2018Review
- Peptide-Mediated Tumor Targeting by a Degradable Nano Gene Delivery Vector Based on Pluronic-Modified Polyethylenimine.Nanoscale research letters · 2016Article
- DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.Oncotarget · 2016Article
- PLGA-loaded nanomedicines in melanoma treatment: Future prospect for efficient drug delivery.The Indian journal of medical research · 2016Review
- Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier.Journal of visualized experiments : JoVE · 2016Article
- Nanoparticles for Effective Combination Therapy of Cancer.International journal of nanotechnology and nanomedicine · 2016Article
- Nanotechnology for cancer treatment.Nanotechnology reviews · 2015Article
- Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy.International journal of nanomedicine · 2015Article
- Nano polymeric carrier fabrication technologies for advanced antitumor therapy.BioMed research international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increased incidence of malignant melanoma in recent decades, along with its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Novel therapeutic strategies, such as immunotherapy and targeted therapy, are urgently needed for melanoma. In this study, a new active targeting drug delivery system was constructed to combine chemotherapy and active specific immunotherapy.
methodsThe chemotherapeutic drug, dacarbazine (DTIC), that induces apoptosis through the intrinsic pathway which typically responds to severe DNA damage, was used as a model drug to prepare DTIC-loaded polylactic acid (PLA) nanoparticles (DTIC-NPs), which were covalently conjugated to a highly specific targeting functional TRAIL-receptor 2 (DR5) monoclonal antibody (mAb) that can contribute directly to cancer cell apoptosis or growth inhibition through the extrinsic pathway.
resultsOur in vitro experiments demonstrated that DTIC-PLA-DR5 mAb nanoparticles (DTIC-NPs-DR5 mAb) are an active targeting drug delivery system which can specifically target DR5-overexpressing malignant melanoma cells and become efficiently internalized. Most strikingly, compared with conventional DTIC-NPs, DTIC-NPs-DR5 mAb showed significantly enhanced cytotoxicity and increased cell apoptosis in DR5-positive malignant melanoma cells.
conclusionThe DTIC-NPs-DR5 mAb described in this paper might be a potential formulation for targeting chemotherapy and immunotherapy to DR5-overexpressing metastatic melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.